Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Laurus Labs Ltd (LAUL)
Laurus Labs Ltd stock price live, this page displays NSE LAUL stock exchange data. View the LAUL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Laurus Labs Ltd real time stock price chart below.
What Is the Laurus Labs Ltd Stock Price Today?
The Laurus Labs Ltd stock price today is 821.85.
What Is the Stock Symbol for Laurus Labs Ltd?
The stock symbol for Laurus Labs Ltd is ""LAUL.""
What Stock Exchange Does Laurus Labs Ltd Trade On?
Laurus Labs Ltd is listed and trades on the NSE stock exchange.
Is Laurus Labs Ltd a Good Stock to Buy?
Determining whether Laurus Labs Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LAUL quote. (ISIN: INE947Q01028)
What Is the Laurus Labs Ltd Stock Price Today?
The Laurus Labs Ltd stock price today is 821.85.
What Is the Stock Symbol for Laurus Labs Ltd?
The stock symbol for Laurus Labs Ltd is ""LAUL.""
What Stock Exchange Does Laurus Labs Ltd Trade On?
Laurus Labs Ltd is listed and trades on the NSE stock exchange.
Is Laurus Labs Ltd a Good Stock to Buy?
Determining whether Laurus Labs Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LAUL quote. (ISIN: INE947Q01028)
821.85
-16.40(-1.96%)
Closed·
Fair Value
An estimate of a Laurus Labs's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
817.55
840.25
52 wk Range
417.70
922.50
LAUL Scorecard
Full Analysis
Net income is expected to grow this year
LAUL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Laurus Labs's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
817.55840.25
52 wk Range
417.70922.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.15%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.15%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
LAUL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Laurus Labs's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
694.85
Downside
-15.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Laurus Labs Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Laurus Labs Ltd Company Profile
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Compare LAUL to Peers and Sector
Metrics to compare | LAUL | Peers Peers - average of corresponding metrics from companies closely matching LAUL: HIKAL, MOREPENLAB, JBCHEPHARM, 524731, NATCOPHARM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLAULPeersSector |
|---|---|---|---|---|
P/E Ratio | 88.9x | 29.5x | −0.5x | |
PEG Ratio | 0.36 | 0.77 | 0.00 | |
Price/Book | 10.1x | 3.0x | 2.6x | |
Price / LTM Sales | 7.6x | 3.7x | 3.3x | |
Upside (Analyst Target) | −18.9% | 16.1% | 43.4% | |
Fair Value Upside | Unlock | 6.4% | 7.1% | Unlock |
Analyst Ratings
4 Buy
2 Hold
7 Sell
Ratings:
13 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 694.85
(-15.45% Downside)
Earnings
Latest Release
Jul 25, 2025
EPS / Forecast
3.00 / 2.11
Revenue / Forecast
15.70B / 14.45B
People Also Watch
FAQ
What Stock Exchange Does Laurus Labs Trade On?
Laurus Labs is listed and trades on the India National Stock Exchange stock exchange.
What Is the Stock Symbol for Laurus Labs?
The stock symbol for Laurus Labs is "LAUL."
What Is the Laurus Labs Market Cap?
As of today, Laurus Labs market cap is 443.74B.
What Is Laurus Labs's Earnings Per Share (TTM)?
The Laurus Labs EPS (TTM) is 9.46.
When Is the Next Laurus Labs Earnings Date?
Laurus Labs will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is LAUL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Laurus Labs Stock Split?
Laurus Labs has split 1 times.
How Many Employees Does Laurus Labs Have?
Laurus Labs has 6167 employees.
What is the current trading status of Laurus Labs (LAUL)?
As of 08 Aug 2025, Laurus Labs (LAUL) is trading at a price of 821.85, with a previous close of 838.25. The stock has fluctuated within a day range of 817.55 to 840.25, while its 52-week range spans from 417.70 to 922.50.
What Is Laurus Labs (LAUL) Price Target According to Analysts?
The average 12-month price target for Laurus Labs is INR694.84615, with a high estimate of INR1025 and a low estimate of INR293. 4 analysts recommend buying the stock, while 7 suggest selling, leading to an overall rating of Neutral. The stock has an -15.45% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.